[Proliferating ability of the lymphocytes of demodectic dogs during immune cell-stimulating therapy].
8 dogs with clinical manifest generalized demodicosis were treated with muramyldipeptide and the multipotent inducer PIND-ORF. Before treatment as well as 10 and 20 days after the beginning of therapy the lymphocyte stimulation indices of these animals were investigated and compared with the values of untreated healthy dogs. In these investigations it was determined that a PIND-ORF and muramyldipeptide therapy has the effect of rising the lymphocyte response to mitogen without, however, reaching the comparative values of healthy dogs.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000627:therapeutic use*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D001688:Biological Products / Q000627:therapeutic use*; D004283:Dog Diseases / Q000276:immunology* / Q000628:therapy; D004285:Dogs; D005260:Female; D008213:Lymphocyte Activation; D008297:Male; D008924:Mite Infestations / Q000276:immunology / Q000628:therapy / Q000662:veterinary*; D008925:Mites
D000276:Adjuvants, Immunologic; D001688:Biological Products; C044867:PIND-ORF; D000119:Acetylmuramyl-Alanyl-Isoglutamine
Zur Proliferationsfähigkeit von Lymphozyten demodikosekranker Hunde bei immunzellstimulierender Therapie.